Regencell Bioscience Holdings annual depreciation and amortization
2020
2021
2022
2023
2024
2025
Regencell Bioscience Holdings Depreciation & Amortization Growth & History (RGC)
Regencell Bioscience Holdings's depreciation and amortization was $392,743 for fiscal 2025.
View full Regencell Bioscience Holdings company overviewRegencell Bioscience Holdings annual depreciation and amortization history
| Fiscal year | Period ended | Depreciation and amortization | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-06-30 | $392,743 | −$352,845 | −47.32% |
| 2024 | 2024-06-30 | $745,588 | −$24,099 | −3.13% |
| 2023 | 2023-06-30 | $769,687 | $165,290 | +27.35% |
| 2022 | 2022-06-30 | $604,397 | $577,941 | +2184.54% |
| 2021 | 2021-06-30 | $26,456 | $16,940 | +178.02% |
| 2020 | 2020-06-30 | $9,516 | — | — |
Regencell Bioscience Holdings depreciation and amortization trends
Over the last five fiscal years, Regencell Bioscience Holdings's depreciation and amortization increased from $9,516 to $392,743, a change of $383,227.
About the metric
What depreciation and amortization mean
Depreciation and amortization allocate the cost of tangible and intangible assets over their useful lives. These non-cash expenses reduce reported earnings and are commonly added back when calculating EBITDA and operating cash flow.
Calculation and source
Reported depreciation and amortization
TickerStat uses a combined depreciation and amortization value when reported. If a company reports the two components separately for an aligned period, they are added together without duplicating overlapping facts. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Regencell Bioscience Holdings source filings ↗